The estimated Net Worth of John T Cavan is at least $417 Tysiąc dollars as of 18 February 2021. Mr Cavan owns over 10,000 units of Hepion Pharmaceuticals Inc stock worth over $11,100 and over the last 8 years he sold HEPA stock worth over $0. In addition, he makes $406,250 as Chief Financial Officer at Hepion Pharmaceuticals Inc.
Sign up
Mr Cavan HEPA stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Hepion Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of HEPA stock worth $20,000 on 18 February 2021.
The largest trade he's ever made was buying 20,000 units of Hepion Pharmaceuticals Inc stock on 20 June 2017 worth over $13,000. On average, Mr trades about 2,875 units every 112 days since 2016. As of 18 February 2021 he still owns at least 14,800 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Mr Cavan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. John T. Cavan biography
John T. Cavan is the Chief Financial Officer at Hepion Pharmaceuticals Inc.
What is the salary of Mr Cavan?
As the Chief Financial Officer of Hepion Pharmaceuticals Inc, the total compensation of Mr Cavan at Hepion Pharmaceuticals Inc is $406,250. There are 3 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.
How old is Mr Cavan?
Mr Cavan is 63, he's been the Chief Financial Officer of Hepion Pharmaceuticals Inc since . There are 6 older and 4 younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.
What's Mr Cavan's mailing address?
John's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.
Insiders trading at Hepion Pharmaceuticals Inc
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard oraz John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.
What does Hepion Pharmaceuticals Inc do?
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
What does Hepion Pharmaceuticals Inc's logo look like?
Complete history of Mr Cavan stock trades at Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Inc executives and stock owners
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Robert Foster,
Chief Executive Officer, Chief Scientific Officer, Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
Pres, CEO & Director -
Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
Pres, CEO & Director -
John T. Cavan,
Chief Financial Officer -
John Cavan,
Chief Financial Officer -
John Brancaccio,
Independent Director -
Timothy Block,
Independent Director -
Arnold Lippa,
Independent Director -
Thomas Adams,
Independent Director -
Gary Jacob,
Chairman of the Board -
Stephen Kilmer,
IR Contact Officer -
Peter Wijngaard,
Independent Director -
Dr. Stephen A. Harrison,
Member of Scientific Advisory Board & Consultant Medical Director -
Dr. John Z. Sullivan-Bolyai,
Part-Time Consultant -
Dr. Todd M. Hobbs M.D.,
Chief Medical Officer -
Dr. Patrick Mayo Ph.D.,
Sr. VP of Clinical Pharmacology -
Dr. Daniel Trepanier Ph.D.,
Sr. VP of Drug Devel. -
Sharen Pyatetskaya,
Director of Investor Relations -
Dr. Daren Ure Ph.D.,
Chief Scientific Officer -
Michael J. Purcell,
Director -
Kaouthar Lbiati,
Director